The Wellcome Trust-MRC Institute of Metabolic Science-Metabolic Research Laboratories (IMS-MRL) and its embedded MRC Metabolic Diseases Unit investigate the mechanisms through which metabolic health is maintained and how this is disturbed in disease.
We seek to use that knowledge to aid better treatment and prevention of obesity, Type 2 diabetes and related endocrine and metabolic diseases.
IMS-MRL groups encompass skills in genetics, cell biology, cell signalling, neuroendocrinology, bioenergetics, human and animal physiology, experimental medicine and clinical trials.
The IMS-MRL is the base for the MRC Metabolic Diseases Unit which supports four programmes of research that aim to improve understanding of the mechanisms responsible for obesity and related metabolic diseases.
Together with a Welcome Strategic Award, it also supports core scientific facilities that underpin basic and experimental science at the IMS-MRL.
Latest News
Study highlights potential long term health risks associated with treatment for gestational diabetes
New research from IMS-MRL researchers published in PLOS Medicine has found that babies whose mothers received treatment with metformin, a…
Stephen O’Rahilly wins Taubman Prize for Excellence in Medical Science
The University of Michigan’s Taubman Institute have today announced that Professor Sir Stephen O’Rahilly will be the 2019 recipient of…
Head of Research Communications named Charity Writer of the year
Congratulations to Craig Brierley, Head of Research Communications for Cambridge University, who was named Charity Writer of the year at…
Dr Amanda Adler wins 2019 NICE Award Distinguished Contribution
Congratulations to Dr Amanda Adler, an IMS colleague and consultant physician specialising in diabetes and metabolic medicine, on receiving a…
